Stock 603127 JOINN LABORATORIES(CHINA)CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Joinn Laboratories(China)Co.,Ltd.

Equities

603127

CNE100002W27

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 08/05/2024 BST 		5-day change 1st Jan Change
18.17 CNY +0.94% Intraday chart for Joinn Laboratories(China)Co.,Ltd. +10.86% -23.37%
04-30 Nomura Adjusts Joinn Laboratories’ Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral MT
04-30 Nomura Adjusts Joinn Laboratories’ Price Target to HK$10.41 From HK$12.60, Keeps at Neutral MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,347 23,453 40,246 29,328 16,313 12,511 - -
Enterprise Value (EV) 1 9,347 23,453 36,161 26,442 13,478 9,246 8,918 8,653
P/E ratio 52.5 x 74.2 x 77 x 29.2 x 44.7 x 48.8 x 20.7 x 19.8 x
Yield 0.59% - 0.31% 0.68% 0.67% 0.16% 1.09% 1.38%
Capitalization / Revenue 14.6 x - 26.5 x 12.9 x 6.86 x 5.31 x 4.46 x 4.57 x
EV / Revenue 14.6 x - 23.8 x 11.7 x 5.67 x 3.93 x 3.18 x 3.16 x
EV / EBITDA - - 71 x 19.8 x 21.5 x 17.1 x 10.1 x 8.1 x
EV / FCF - - 80.8 x 38 x 31.3 x 12.4 x 22.5 x 21.8 x
FCF Yield - - 1.24% 2.63% 3.19% 8.1% 4.44% 4.58%
Price to Book 11.3 x - 6.16 x 3.82 x 2.15 x 1.59 x 1.46 x 1.41 x
Nbr of stocks (in thousands) 621,252 624,136 747,243 749,950 746,974 746,974 - -
Reference price 2 15.05 37.58 58.89 41.72 23.71 18.17 18.17 18.17
Announcement Date 12/04/20 29/03/21 24/02/22 30/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 639.4 - 1,517 2,268 2,376 2,354 2,802 2,739
EBITDA 1 - - 509.1 1,333 626.1 540.8 883.6 1,068
EBIT 1 206.1 - 407.6 1,226 507.1 359.5 656.8 789.9
Operating Margin 32.24% - 26.88% 54.04% 21.34% 15.27% 23.44% 28.84%
Earnings before Tax (EBT) 1 205.9 - 642 1,240 507 45.75 707.2 827.4
Net income 1 178.4 315 557.5 1,074 397 26.18 597.9 693.8
Net margin 27.9% - 36.76% 47.37% 16.71% 1.11% 21.34% 25.33%
EPS 2 0.2863 0.5066 0.7653 1.429 0.5300 0.3721 0.8765 0.9155
Free Cash Flow 1 - - 447.4 696.3 430.3 748.6 396.4 396.1
FCF margin - - 29.5% 30.7% 18.11% 31.8% 14.14% 14.46%
FCF Conversion (EBITDA) - - 87.88% 52.25% 68.73% 138.43% 44.86% 37.09%
FCF Conversion (Net income) - - 80.26% 64.82% 108.39% 2,859.41% 66.29% 57.08%
Dividend per Share 2 0.0885 - 0.1837 0.2857 0.1600 0.0284 0.1973 0.2512
Announcement Date 12/04/20 29/03/21 24/02/22 30/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - 499.5 991.6 1,491 369.4 642.7 575 789.4 324.8 609.1 602.4 831.9 - -
EBITDA - - 168.6 - - - - - - - - - - - -
EBIT 1 - - 297.1 507.9 805 214.4 - 275.2 115 - 139.6 126.9 175.2 - -
Operating Margin - - 59.48% 51.22% 53.99% 58.03% - 47.87% 14.57% - 22.92% 21.06% 21.06% - -
Earnings before Tax (EBT) - - - 507.8 804.9 214.3 -97.39 275 115 - - - - - -
Net income 125.3 245.8 260.9 442.2 703.1 187.8 -97.13 237 69.39 - - - - - -
Net margin - - 52.23% 44.6% 47.16% 50.83% -15.11% 41.21% 8.79% - - - - - -
EPS 2 0.1684 - 0.3500 0.5857 - 0.2500 -0.0800 0.3200 0.0900 -0.3600 0.1000 0.0800 0.1000 - -
Dividend per Share 2 - - - - - - - - - - - - 0.0284 - -
Announcement Date 28/04/22 30/08/22 28/10/22 30/03/23 30/03/23 27/04/23 30/08/23 30/10/23 28/03/24 29/04/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - 4,085 2,886 2,835 3,264 3,593 3,858
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - 447 696 430 749 396 396
ROE (net income / shareholders' equity) 24.4% 30.8% 13.3% 14% 4.82% 0.29% 6.55% 7.61%
ROA (Net income/ Total Assets) 13.9% - 10.4% 11.4% - 4.16% 5.01% 5.21%
Assets 1 1,280 - 5,355 9,451 - 630 11,928 13,312
Book Value Per Share 2 1.330 - 9.560 10.90 11.00 11.40 12.40 12.90
Cash Flow per Share 2 0.2400 - 0.9400 1.290 0.8300 1.040 0.8500 1.190
Capex 1 127 - 237 275 193 246 226 236
Capex / Sales 19.83% - 15.64% 12.11% 8.1% 10.45% 8.07% 8.6%
Announcement Date 12/04/20 29/03/21 24/02/22 30/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Joinn Laboratories(China)Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
18.17 CNY
Average target price
18.66 CNY
Spread / Average Target
+2.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
JOINN LABORATORIES(CHINA)CO.,LTD. Stock Joinn Laboratories(China)Co.,Ltd.
-23.37% 1.73B
MODERNA, INC. Stock Moderna, Inc.
+23.37% 47.02B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.94% 41.76B
CELLTRION, INC. Stock Celltrion, Inc.
-5.86% 28.8B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.29% 26.05B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.92% 19.15B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+3.20% 12.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.67% 11.82B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.23% 12.34B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 603127 Stock
  4. Financials Joinn Laboratories(China)Co.,Ltd.